About Receptos (NASDAQ:RCPT)
Receptos, Inc. (Receptos) is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing therapeutics in immune disorders. Its product candidates span three disease areas. It is developing its lead asset, ozanimod (formerly RPC1063), as an oral therapy for the treatment of Relapsing Multiple Sclerosis (RMS) and Inflammatory Bowel Disease (IBD), which consists of Ulcerative Colitis (UC) and Crohn's Disease (CD). It is developing its second asset, RPC4046, for the treatment of an allergic/immune-mediated disorder, Eosinophilic Esophagitis (EoE), for which it has been granted Orphan drug designation. Its research efforts include a preclinical program developing oral, small molecule, positive allosteric modulators (PAMs) of the glucagon-like peptide-1 receptor (GLP-1R) for the treatment of Type 2 Diabetes.
Industry, Sector and Symbol
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
EPS (Most Recent Fiscal Year)N/A
Return on Equity-44.89%
Return on Assets-41.50%
Receptos (NASDAQ:RCPT) Frequently Asked Questions
What is Receptos' stock symbol?
Receptos trades on the NASDAQ under the ticker symbol "RCPT."
How were Receptos' earnings last quarter?
Receptos Inc (NASDAQ:RCPT) posted its earnings results on Tuesday, May, 5th. The biopharmaceutical company reported ($1.29) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($1.09) by $0.20. View Receptos' Earnings History.
Has Receptos been receiving favorable news coverage?
Headlines about RCPT stock have trended somewhat positive this week, Accern Sentiment Analysis reports. Accern ranks the sentiment of media coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Receptos earned a news impact score of 0.14 on Accern's scale. They also gave media stories about the biopharmaceutical company an impact score of 45.21 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the next few days.
How do I buy shares of Receptos?
Shares of RCPT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How can I contact Receptos?
Receptos' mailing address is 3033 Science Park Road, Suite 300, SAN DIEGO, CA 92121, United States. The biopharmaceutical company can be reached via phone at +1-858-6525700.
MarketBeat Community Rating for Receptos (RCPT)MarketBeat's community ratings are surveys of what our community members think about Receptos and other stocks. Vote "Outperform" if you believe RCPT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RCPT will underperform the S&P 500 over the long term. You may vote once every thirty days.
Receptos (NASDAQ:RCPT) Analyst Ratings History
(Data available from 4/25/2016 forward)
|Date||Brokerage||Action||Rating||Price Target||Impact on Share Price||Details|
Receptos (NASDAQ:RCPT) Earnings History and Estimates Chart
Receptos (NASDAQ RCPT) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|11/4/2014||Q314||($0.96)||($1.19)||$1.00 million||$3.45 million||View||N/A|
|8/12/2014||Q214||($0.85)||($1.04)||$1.28 million||$1.10 million||View||N/A|
|5/12/2014||Q114||($0.84)||($1.01)||$0.49 million||$1.40 million||View||N/A|
|3/5/2014||($0.86)||($0.86)||$1.16 million||$0.77 million||View||N/A|
|8/7/2013||Q2 2013||($0.56)||($0.98)||$0.54 million||$1.24 million||View||N/A|
Receptos (NASDAQ:RCPT) Dividend History by Quarter
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
Receptos (NASDAQ RCPT) Insider Trading and Institutional Ownership History
Receptos (NASDAQ RCPT) Insider Trading History
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|6/16/2015||S. Edward Torres||Director||Sell||220,000||$178.99||$39,377,800.00|| |
|2/23/2015||S. Edward Torres||Director||Sell||47,906||$128.20||$6,141,549.20|| |
|11/11/2014||Faheem Hasnain||CEO||Sell||200,000||$109.47||$21,894,000.00|| |
|11/11/2014||Sheila Gujrathi||Insider||Sell||30,000||$108.99||$3,269,700.00|| |
|11/10/2014||Chrysa Mineo||SVP||Sell||30,000||$109.73||$3,291,900.00|| |
|11/10/2014||Faheem Hasnain||CEO||Sell||136,795||$109.69||$15,005,043.55|| |
|11/10/2014||Marcus F Boehm||CTO||Sell||40,454||$109.91||$4,446,299.14|| |
|9/23/2014||S. Edward Torres||Director||Sell||100,000||$61.36||$6,136,000.00|| |
|9/22/2014||S. Edward Torres||Director||Sell||14,318||$63.08||$903,179.44|| |
|9/22/2014||Sheila Gujrathi||Insider||Sell||30,000||$61.45||$1,843,500.00|| |
|9/19/2014||S. Edward Torres||Director||Sell||169,570||$62.55||$10,606,603.50|| |
|9/18/2014||S. Edward Torres||Director||Sell||91,513||$62.77||$5,744,271.01|| |
|9/17/2014||David A Hinkle||CAO||Sell||2,000||$64.82||$129,640.00|| |
|9/17/2014||S. Edward Torres||Director||Sell||38,917||$63.67||$2,477,845.39|| |
|9/16/2014||Graham K Cooper||CFO||Sell||50,000||$61.30||$3,065,000.00|| |
|9/2/2014||David A Hinkle||CAO||Sell||2,000||$52.80||$105,600.00|| |
|8/13/2014||David A Hinkle||CAO||Sell||3,000||$42.69||$128,070.00|| |
|8/13/2014||S. Edward Torres||Director||Sell||200,000||$43.24||$8,648,000.00|| |
|5/29/2014||Kristina Burow||Director||Sell||153,698||$29.74||$4,570,978.52|| |
|5/21/2014||S. Edward Torres||Director||Sell||424,068||$25.26||$10,711,957.68|| |
|5/15/2014||S. Edward Torres||Director||Sell||90,075||$27.37||$2,465,352.75|| |
|5/14/2014||Kristina Burow||Director||Sell||45,381||$29.66||$1,346,000.46||13,333|| |
|1/3/2014||William Rastetter||Director||Sell||37,359||$30.85||$1,152,525.15|| |
|1/2/2014||William Rastetter||Director||Sell||27,581||$30.29||$835,428.49|| |
|12/6/2013||Amir Nashat||Director||Sell||170,000||$26.70||$4,539,000.00|| |
|12/5/2013||William Rastetter||Director||Sell||500,000||$27.63||$13,815,000.00|| |
|11/18/2013||Ventures Fund 2007 Flagship||major shareholder||Sell||230,787||$24.75||$5,711,978.25|| |
|11/15/2013||Amir Nashat||Director||Sell||169,315||$24.96||$4,226,102.40|| |
|5/14/2013||Amir Nashat||Director||Buy||151,343||$14.00||$2,118,802.00|| |
|5/14/2013||Ventures Fund 2007 L Flagship||Major Shareholder||Buy||107,142||$14.00||$1,499,988.00|| |
Receptos (NASDAQ RCPT) News Headlines
Receptos (NASDAQ:RCPT) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Receptos (NASDAQ:RCPT) Income Statement, Balance Sheet and Cash Flow Statement
Receptos (NASDAQ RCPT) Stock Chart for Wednesday, April, 25, 2018